Investor Presentation

Here's a summary of the attached document: **1. Financial Highlights:** Q1 FY26: Rossari Biotech revenue Rs. 543.7 Cr (+11% YoY), EBITDA Rs. 67.9 Cr (+5% YoY, 12.5% margin), PAT Rs. 33.6 Cr (-4% YoY, 6.2% margin). HPPC drove 78% revenue.

Core business resilient with ~16% adjusted EBITDA margin.

Expect improved returns as investments mature. **2. Strategic Initiatives & Growth Drivers:** Capacity expansion projects for high-growth sectors (personal care, agrochemicals, pharma) are commissioning soon, poised to drive FY27+ growth.

Firm also focusing on green solutions & new business lines to diversify its portfolio. **3. Business Developments:** HPPC (+16%) and AHN (+12%) showed robust growth, expanding customer reach.

Institutional & B2C segments grew 9% YoY, incubating future potential.

Strategic acquisitions successfully expanded market reach & capabilities. **4. Market Position & Competitive Advantage:** Leading specialty chemical player with 7 plants, 4 R&D centers, serving 1,000+ global customers.

Asset-light model, sustainable product focus, and strong client ties provide a distinct competitive advantage. **5. Investor Implications:** Consistent growth & strategic capacity additions signal positive growth potential.

Investors: monitor efficient ramp-up of new capacities & expected improvement in financial returns.